Tag: Biotech and Pharma

Novartis said on Wednesday it intends to build a radioligand therapy manufacturing site in Texas, ‌expanding its U.S. footprint with what will be ‌its first such facility in the state and fifth nationwide.

GSK (GSK) has agreed to pay $950 million in cash for Canadian biotech 35Pharma, it said on Wednesday, marking the second major deal new CEO Luke Miels has struck to accelerate development of new medicines at the British drugmaker.

Fresenius Medical Care AG (FMS) reported fourth-quarter adjusted earnings per share of EUR 1.44, beating expectations.

Hims & Hers Health (HIMS) stock fell after the telehealth company posted mixed quarterly results and issued a weak outlook for the current quarter.

Novo’s drug, CagriSema, didn’t achieve its key goal of demonstrating non-inferiority on weight loss when compared to Eli Lilly’s rival drug tirzepatide.

Gilead Sciences agrees to acquire biotech company Arcellx for $7.8 billion.

Shares of Moderna (MRNA) slipped Friday after the drugmaker reported better-than-expected quarterly results.

Gilead Sciences (GILD) reported its fourth-quarter and full-year 2025 financial results on February 10, 2026, highlighting strong performance in its base business despite competitive pressures in certain segments. The company’s stock declined 0.94% in aftermarket trading to $150.26, despite exceeding analyst expectations for both revenue and earnings.

AstraZeneca PLC’s (AZN) full-year results showed the pharmaceutical group navigating a challenging comparison period with a robust operational performance and a renewed commitment to long-term growth, analysts said.

Eli Lilly (LLY) will buy therapy developer Orna Therapeutics for up to $2.4 billion in cash, the companies said on Monday.

Novo Nordisk on Monday said it is suing online telehealth provider Hims & Hers for mass marketing cheaper, unapproved copies of the drugmaker’s new Wegovy obesity pill and injections in the U.S.

Biogen Inc. forecast 2026 profit above Wall Street’s expectations, signaling that steep cost-cutting measures are cushioning the impact of shrinking sales from its multiple sclerosis franchise.

The stock of Hims & Hers dropped in premarket trading early Friday after a legal threat from Novo Nordisk.

Bristol Myers Squibb (BMY) rose Thursday on the back of better-than-expected fourth-quarter earnings but most encouraging was an upbeat outlook from the drugmaker.

GSK Plc reported better-than-expected profit in the fourth quarter, buoyed by its HIV and asthma medicines.

AbbVie forecast 2026 profit above Wall Street estimates on Wednesday after posting a fourth-quarter results beat, fueled by strong ​demand for newer immunology drugs Skyrizi and Rinvoq and a smaller-than-expected ‌decline in sales of its older medicine Humira.

Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise pre-released its 2026 forecast late Tuesday, sending shares tumbling.

Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars.

Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, while reaffirming its modest 2026 guidance that rattled investors in December.

Merck & Co. (MRK) shares have dropped 1.6% premarket on Tuesday after the pharmaceutical giant issued 2026 guidance below analyst expectations, overshadowing solid fourth-quarter results that met earnings forecasts and slightly exceeded revenue estimates.